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criteria were eligible for the study. Overall, 103 patients were found to be eligible and were included in the study. The mean age of the patients was 55.4 (+/-12.1) years. Thirty-one per cent of the patients were older than 60 years.
Study design
The analysis was based on a retrospective, single-centred cohort study, specifically a retrospective medical record review. Data from medical records were collected for each patient, for 1 month before conversion and for 6 months after.
Analysis of effectiveness
It was not reported whether all of the patients included in the study were considered at analysis. The primary outcomes assessed were the mean daily doses taken by patients when receiving sustained-release bupropion at conversion and immediate-release bupropion 6 months after conversion. Differences in these outcomes were compared using Student's t-test. Further outcomes were the mean single dose of immediate-release bupropion and the frequency of adverse events (i.e. seizure, headache, agitation or anxiety, chest pain, gastrointestinal complaints and death). The rates of adverse events were compared using the chi-squared test. A p value less than or equal to 0.05 was declared statistically significant.
Effectiveness results
The results were reported separately for those aged over 60 years, for patients who received bupropion for smoking cessation, and for patients who received it because of a psychiatric diagnosis.
Mean daily doses of sustained-release bupropion at conversion did not differ significantly from mean daily doses of immediate-release bupropion at 6 months after conversion, (p=0.73).
Although four deaths occurred during the study period, they were found to be unrelated to bupropion therapy or the change in dosage form.
Four patients (5.6%) out of 71 under the age of 60 years and 3 patients out of 32 over the age of 60 experienced nonfatal adverse events after conversion. The difference was not statistically significant, (p=0.485, chi-squared test). Patients aged 60 years and older received smaller mean daily doses of immediate-release bupropion at the end of the follow-up period compared with patients younger than 60 years, but the difference in mean doses was not statistically significant (279.7 +/-91.5 mg versus 303.2 +/-84.9 mg; p=0.223, Student's t-test).
Compared with patients with psychiatric diagnoses, patients who received bupropion for smoking cessation did not demonstrate a statistically significant adverse event rate (6% versus 8.1%; p=0.810, chi-squared test). The mean daily doses of immediate-release bupropion at the end of the follow-up period also did not vary significantly (300 +/-75 mg for the smoking-cessation group versus 295 +/-90 mg for the group with psychiatric diagnoses; p=0.832, Student's ttest).
The most frequent dosage of immediate-release bupropion at the end of the follow-up period was 300 mg/day in each group. Dosages different from 300 mg/day were administered to 4 patients (25%) in the smoking-cessation group and 36 patients (41%) in the group of patients with psychiatric diagnoses.
Clinical conclusions
The authors concluded "conversion from sustained-release bupropion to immediate-release bupropion appears to be safe". The analysis proved that immediate-release bupropion can be administered to patients without them experiencing disproportionate adverse events including seizure.
